Tarceva erlotinib: Complete Phase III enrollment

DNA expects to complete enrollment of 650 patients in the Phase III BETA Lung trial evaluating Tarceva plus either Avastin bevacizumab or placebo as second-line treatment for metastatic non-squamous ...